stars 1 stars 2 stars 3

Oncovision is a leading provider of innovative medical imaging devices used by surgeons, radiologists, oncologists and nuclear physicians for the diagnosis and treatment of cancer. Oncovision has grown into a dynamic brand in a technologically competitive, high-growth industry. Oncovision has offices in Boston, USA and Valencia, Spain and sells its products in over 30 markets through a combination of direct sales and distributors. Through a strong internal pipeline, Oncovision boasts a clinical and preclinical product line. Clinical product line includes market-leading Sentinella, a unique intra-operative Gamma Camera and the revolutionary MAMMI PET, a breast cancer diagnostic device capable of visualising lesions of less than 2mm and quantifying tumor activity. Oncovision completes its portfolio with Wprobe, the gold standard in radioguided surgery and Albira a device leading preclinical research to new levels. Oncovision has distinguished itself through the ability to successfully develop and bring to the market innovative products to generate significant benefits on patients, and is committed to continue that trend. Also, the company plans to bring forth technical and clinical solutions for an accurate diagnosis and treatment of cancer, providing the highest-quality, best-performing products.

Oncovision Questions

The Oncovision annual revenue was $17.1 million in 2026.

Juan Catret is the CTO of Oncovision.

25 people are employed at Oncovision.

The NAICS codes for Oncovision are [33, 334].

The SIC codes for Oncovision are [384, 38].

Top Oncovision Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users